NEW YORK, July 7 - Linden Bioscience said today that it has licensed mRNA amplification technology from Incyte to be used in an RNA amplification and archival kit based upon Linden Bioscience's solid phase transcription chain reaction (SP-TCR) technology.
Linden entered a non-exclusive license agreement for linear mRNA amplification technology protected by three US patents (5,716,785; 5,891,636; and 6,291,170) assigned to the Board of Trustees of Leland Stanford Junior University and exclusively licensed to Incyte. Linear amplification technology is based upon antisense RNA amplification, which, according to Linden, is able to maintain the relative ratios of the starting mRNA population better than exponential amplification methods such as nucleic acid sequence-based amplification or RT-PCR.
The combination of Linden's and Incyte's RNA technologies will "produce quantities of RNA sufficient for gene expression profiling experiments without the need for large amounts of initial mRNA sample," according to Linden. The combined technology will also allow researchers to store and later amplify the mRNA of interest without introducing bias in the amplified product, the company said.
Linden said the new amplification product would be available "in the next few months."